{"id":"W1533769407","doi":"10.1038/cddis.2015.187","title":"FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing","year":2015,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"Leukemia and Lymphoma Society","keywords":"Pharmacology; Pharmacokinetics; Proteasome; Proteasome inhibitor; Dosing; Multiple myeloma; Pharmacodynamics; Tolerability; Bioavailability; In vivo; Prodrug; Bortezomib; Medicine; Chemistry; Biology; Immunology; Adverse effect; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001900115,0.0003412672,0.0002634794,0.00004629585,0.0001424352,0.0001314541,0.0001821056,0.0001271965,0.00002662734],"category_scores_gemma":[0.00009025045,0.0002592428,0.0000701227,0.0001025492,0.0001674943,0.00002074023,0.0001565513,0.0001734388,0.0000175129],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001645224,"about_ca_system_score_gemma":0.000529912,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002087145,"about_ca_topic_score_gemma":0.000002929176,"domain_scores_codex":[0.9983202,0.00005316133,0.0002496859,0.0006880226,0.0002250434,0.0004639325],"domain_scores_gemma":[0.9980489,0.00002206097,0.0001460023,0.0003968491,0.0001653673,0.00122084],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01889051,0.002080139,0.1100757,0.0007111121,0.0002496509,0.0001679469,0.0004596,0.00008373197,0.8557866,0.00003934556,0.007718465,0.003737207],"study_design_scores_gemma":[0.04665065,0.008067319,0.008451183,0.0005294773,0.001186404,0.0001080938,0.000467287,0.003077851,0.8166574,0.00008867199,0.1118402,0.00287541],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932675,0.002570534,0.001394618,0.0001858131,0.00008776796,0.001067478,0.0001643715,0.00004573187,0.001216149],"genre_scores_gemma":[0.9926457,0.00009136411,0.004224069,0.0009130336,0.0003180081,0.00008481346,0.0001635885,0.00005656758,0.001502833],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1041218,"threshold_uncertainty_score":0.999986,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02637827595721043,"score_gpt":0.265230519640434,"score_spread":0.2388522436832236,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}